Literature DB >> 16185933

Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation.

Anna-Karin Roos1, Sonia Moreno, Christoph Leder, Maxim Pavlenko, Alan King, Pavel Pisa.   

Abstract

Recently it has become clear that more potent methods for DNA vaccine delivery need to be developed to enhance the efficacy of DNA vaccines. In vivo electroporation has emerged as a potent method for DNA vaccine delivery. In a mouse model, we evaluated the CD8(+) T lymphocyte response to a prostate cancer DNA vaccine encoding prostate-specific antigen (PSA) after intradermal electroporation. A significantly increased gene expression (100- to 1000-fold) and higher levels of PSA-specific T cells, compared to DNA delivery without electroporation, was demonstrated. Interestingly, investigation of a panel of different electroporation conditions showed that only some conditions that induce high levels of gene expression additionally induced cellular immunity. This suggests that electroporation parameters should be carefully optimized, not only to enhance transfection efficiency, but also to enhance the immune response to the vaccine. This study demonstrates the applicability of intradermal electroporation as a delivery method for genetic cancer vaccines and other DNA vaccines relying on antigen-specific T cell induction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16185933     DOI: 10.1016/j.ymthe.2005.08.005

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine.

Authors:  Maria L Knudsen; Alice Mbewe-Mvula; Maximillian Rosario; Daniel X Johansson; Maria Kakoulidou; Anne Bridgeman; Arturo Reyes-Sandoval; Alfredo Nicosia; Karl Ljungberg; Tomás Hanke; Peter Liljeström
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses.

Authors:  Natalie A Hutnick; Devin J F Myles; Bernadette Ferraro; Colleen Lucke; Feng Lin; Jian Yan; Kate E Broderick; Amir S Khan; Niranjian Y Sardesai; David B Weiner
Journal:  Hum Gene Ther       Date:  2012-08-02       Impact factor: 5.695

3.  Skin Transfection Patterns and Expression Kinetics of Electroporation-Enhanced Plasmid Delivery Using the CELLECTRA-3P, a Portable Next-Generation Dermal Electroporation Device.

Authors:  Dinah H Amante; Trevor R F Smith; Janess M Mendoza; Katherine Schultheis; Jay R McCoy; Amir S Khan; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Gene Ther Methods       Date:  2015-08       Impact factor: 2.396

4.  Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults.

Authors:  Samer S El-Kamary; Melissa Billington; Stephen Deitz; Elaina Colby; Howard Rhinehart; Yukun Wu; William Blackwelder; Robert Edelman; Albert Lee; Alan King
Journal:  Mol Ther       Date:  2011-11-08       Impact factor: 11.454

5.  Transfection by electroporation.

Authors:  Huntington Potter
Journal:  Curr Protoc Mol Biol       Date:  2003-05

Review 6.  Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments.

Authors:  Angela M Bodles-Brakhop; Richard Heller; Ruxandra Draghia-Akli
Journal:  Mol Ther       Date:  2009-02-17       Impact factor: 11.454

7.  DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza.

Authors:  Gunnveig Grodeland; Siri Mjaaland; Kenneth H Roux; Agnete Brunsvik Fredriksen; Bjarne Bogen
Journal:  J Immunol       Date:  2013-08-16       Impact factor: 5.422

8.  In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.

Authors:  Qingtao Wang; Wei Jiang; Yuhai Chen; Pengyu Liu; Chunjie Sheng; Shuai Chen; Hui Zhang; Changchuan Pan; Shijuan Gao; Wenlin Huang
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Tolerability of intramuscular and intradermal delivery by CELLECTRA(®) adaptive constant current electroporation device in healthy volunteers.

Authors:  Malissa C Diehl; Jessica C Lee; Stephen E Daniels; Pablo Tebas; Amir S Khan; Mary Giffear; Niranjan Y Sardesai; Mark L Bagarazzi
Journal:  Hum Vaccin Immunother       Date:  2013-06-04       Impact factor: 3.452

10.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.